Although sales fell in the first half at Imaginatik, a software provider that enables large corporations to tap into the ‘collective genius’ of their staff, long-term prospects improved as the company switched its focus from smaller projects to large.
A ‘tougher-than-expected’ first quarter led to sales shrinking 9% to £1.2m for the six months to September, with a £470,000 pre-tax loss dragging cash levels back to £108,000. The dollar effect has not been too deleterious, despite most clients being US-based, as most costs are incurred in that beleaguered currency.
Increased momentum in the second quarter, with new US business wins including Xerox, Kellogg’s and Philip Morris and new pilots in the UK including BSkyB and Merrill Lynch, has continued into the second half, with the company's collaboration with IBM starting to reap rewards.
A previous deal with IBM, whose activities in the area it calls ‘ideation’ are well known in corporate America, was upgraded to a global reselling agreement in August. No impact was reflected in the interim figures, but in October IBM’s sales team was trained up to sell Imaginatik’s solution, which should dramatically increase prospects.
In the second half, four one-off ‘ideation’ projects have already been signed and CEO Mark Turrell is working with IBM to sell more long-term contracts. The London-based company’s efforts to increase recurring revenues saw it sign eight long-term deals in the first half, giving it 40 clients that now pay some form of annual fee.
Together, Imaginatik and IBM have around 70% of a booming market and house broker WH Ireland predicts 70% sales growth this year and next. Volatile since listing at 7.5p in December, Imaginatik has speculative potential with bids a possibility.
Growth Company Investor subscribers have full access to all our AIM and small-cap share recommendations. To subscribe today with a half-price offer, and gain immediate access to all the recommendations, click here.
Market cap: £6.56m
PE Forecast: 14
Share price: 5.63p
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Advertisement
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.